neurological conditions – Talk Bio

Actionable Insights Powered by AI

Ionis Advances to Phase 3 Trial for Angelman Syndrome Treatment ION582

9 months ago talkbio0Tagged Angelman Syndrome, Antisense, Biogen, Dosage Forms, ION582, Ionis Pharmaceuticals, neurological conditions, Oligonucleotides, Phase 3 trial, Ultragenyx

Ionis Pharmaceuticals, Angelman syndrome, ION582, Phase 3 trial, antisense oligonucleotides, neurological conditions, rare diseases, Biogen, Ultragenyx Pharmaceutical